Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis antifungals

This article was originally published in The Tan Sheet

Executive Summary

Soltec Research grants exclusive global license for Liquipatch topical drug delivery technology to Novartis for all antifungal applications, Soltec parent Connetics announces April 8. Novartis previously licensed the technology only for use in its Lamisil line. In addition to paying Soltec an undisclosed sum to expand the license, Novartis will continue to pay product development costs, licensing fees, sales royalties and milestone payments. Liquipatch applies to skin "like a conventional topical gel and dries to form a thin, invisible, water-resistant film," Connetics says...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS093888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel